Jim Wu

Company: Ark Biosciences

Job title: CEO

Seminars:

Workshop C Comparatively Assess Novel & Disease- Specific Targets vs. Upstream Broad-Spectrum Targets to Unveil Untapped Opportunities for Enhanced IPF Therapeutics 11:30 am

• Exploring specific and isolated drivers of IPF including ECM, fibroblasts, macrophages, epithelial and endothelial cells as opposed to generic processes • Minimizing off target effects with novel disease-specific pathways and targets to halt fibrosis with greater precision • Targeting upstream non-specific processes affecting multiple downstream pro-fibrotic pathways • Finding the balance between strength and…Read more

day: Pre-Conference Workshop C

Unveiling Progress: Clinical Trial Design & Strategic Insights from Phase 2 Clinical Program in IPF 2:00 pm

• Exploring the intricacies of the clinical trial design for AK3280 in IPF, including patient selection criteria, endpoint selection, and the overall study methodology • How the trial design addresses the unique challenges posed by IPF in the Chinese patient population, showcasing adaptations made to enhance efficacy and relevance • Insights into the regulatory landscape…Read more

day: Day Two Track B PM